These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34058991)

  • 1. Cycle length of nonsustanied ventricular tachycardias among ICD patients: implications on subsequent appropriate therapies.
    Jiménez-Candil J; Duran O; Oterino A; Pérez J; Castro JC; Hernández J; Moríñigo J; García MS; Sánchez PL
    BMC Cardiovasc Disord; 2021 May; 21(1):268. PubMed ID: 34058991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Nonsustained Ventricular Tachycardia Episodes Occurring Early After Implantable Cardioverter-Defibrillator Implantation Among Patients With Left Ventricular Dysfunction.
    Jiménez-Candil J; Hernández J; Perdiguero P; Martín A; Moríñigo J; Bravo L; Durán O; Sánchez PL
    Am J Cardiol; 2016 Nov; 118(10):1503-1510. PubMed ID: 27634031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
    Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 5. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
    Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication.
    Schaer B; Kühne M; Reichlin T; Osswald S; Sticherling C
    Europace; 2016 Feb; 18(2):227-31. PubMed ID: 26063686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
    Link MS; Bockstall K; Weinstock J; Alsheikh-Ali AA; Semsarian C; Estes NAM; Spirito P; Haas TS; Rowin EJ; Maron MS; Maron BJ
    J Cardiovasc Electrophysiol; 2017 May; 28(5):531-537. PubMed ID: 28240435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophysiologic study: its predictive value for ventricular arrhythmias.
    Gold DR; Catanzaro JN; Makaryus JN; Waldman C; Sauer WH; Sison C; Makaryus AN; Altman E; Jadonath R; Beldner S
    Tex Heart Inst J; 2010; 37(3):291-6. PubMed ID: 20548804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of nonsustained ventricular tachycardia morphology in high-risk patients with hypertrophic cardiomyopathy.
    Adduci C; Boldini F; Palano F; Musumeci B; De Lucia C; Russo D; Volpe M; Autore C; Francia P
    J Cardiovasc Electrophysiol; 2020 Aug; 31(8):2093-2098. PubMed ID: 32437006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of high-rate cutoff and long detection interval ICD programming in secondary prevention patients.
    Hayashi Y; Takagi M; Kakihara J; Sakamoto S; Doi A; Sugioka K; Hanatani A; Yoshiyama M
    Heart Vessels; 2017 Feb; 32(2):175-185. PubMed ID: 27259484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. J Waves Are Associated With the Increased Occurrence of Life-Threatening Ventricular Tachyarrhythmia in Patients With Nonischemic Cardiomyopathy.
    Naruse Y; Nogami A; Shinoda Y; Hanaki Y; Shirai Y; Kowase S; Kurosaki K; Machino T; Kuroki K; Yamasaki H; Igarashi M; Sekiguchi Y; Aonuma K
    J Cardiovasc Electrophysiol; 2016 Dec; 27(12):1448-1453. PubMed ID: 27593399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation increases the risk of recurrent ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients.
    Rusnak J; Behnes M; Reiser L; Schupp T; Bollow A; Reichelt T; Borggrefe M; Ellguth D; Engelke N; El-Battrawy I; Ansari U; Barre M; Weidner K; Müller J; Barth C; Meininghaus DG; Akin M; Bertsch T; Taton G; Akin I
    Arch Cardiovasc Dis; 2021; 114(6-7):443-454. PubMed ID: 33967015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second coupling interval of nonsustained ventricular tachycardia to distinguish malignant from benign outflow tract ventricular tachycardias.
    Kim YR; Nam GB; Kwon CH; Lee WS; Kim YG; Hwang KW; Kim J; Choi KJ; Kim YH
    Heart Rhythm; 2014 Dec; 11(12):2222-30. PubMed ID: 25111325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scar extent as a predictive factor of ventricular tachycardia cycle length after myocardial infarction: implications for implantable cardioverter-defibrillator programming optimization.
    Alexandre J; Saloux E; Lebon A; Dugué AE; Lemaitre A; Roule V; Labombarda F; Champ-Rigot L; Gomes S; Pellissier A; Scanu P; Milliez P
    Europace; 2014 Feb; 16(2):220-6. PubMed ID: 24186956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SVT discrimination algorithms significantly reduce the rate of inappropriate therapy in the setting of modern-day delayed high-rate detection programming.
    Cheng A; Auricchio A; Schloss EJ; Kurita T; Sterns LD; Gerritse B; Brown ML; Fagan DH; Lexcen DR; Ellenbogen KA
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2877-2884. PubMed ID: 31646695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and Implantable Cardioverter-Defibrillator Therapies.
    Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I
    J Cardiovasc Pharmacol; 2019 May; 73(5):272-281. PubMed ID: 30747784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.